Literature DB >> 14658054

Plasma amino acids percentages in amyotrophic lateral sclerosis patients.

J Iłzecka1, Z Stelmasiak, J Solski, S Wawrzycki, M Szpetnar.   

Abstract

The aim of the study was to examine plasma amino acids (AA) percentages in amyotrophic lateral sclerosis (ALS) patients. Altered metabolism of AA, especially excitatory AA in ALS, has been reported. The investigation was conducted at the Department of Neurology, University School of Medicine in Lublin. The study comprised 50 patients; 20 persons with ALS and 30 controls. Plasma AA were measured by automated ion-exchange chromatography. The results show significantly lower percentages of plasma tyrosine, valine, methionine, leucine, and isoleucine and significantly higher percentages of plasma glutamine and serine in ALS than in controls. The clinical state significantly influenced the percentage of plasma phenylalanine and alanine. Our study shows significant changes in some plasma AA percentages in ALS; however, excitatory AA percentages did not differ from the control subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14658054     DOI: 10.1007/s10072-003-0161-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

Review 1.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Dysregulated expression of death, stress and mitochondrion related genes in the sciatic nerve of presymptomatic SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis.

Authors:  Chrystian J Alves; Jessica R Maximino; Gerson Chadi
Journal:  Front Cell Neurosci       Date:  2015-09-01       Impact factor: 5.505

3.  Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy.

Authors:  Qi-Jie Zhang; Yang Chen; Xiao-Huan Zou; Wei Hu; Min-Lu Ye; Qi-Fu Guo; Xue-Liang Lin; Shang-Yuan Feng; Ning Wang
Journal:  Ann Clin Transl Neurol       Date:  2020-09-19       Impact factor: 4.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.